A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
about
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial VirusEGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin ExpressionRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuationAntigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeMolecular mechanism of respiratory syncytial virus fusion inhibitors.Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSVVaccines against respiratory syncytial virus: The time has finally come.Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability.Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.Immobilization of the N-terminal helix stabilizes prefusion paramyxovirus fusion proteins.Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus.Flexibility of the Head-Stalk Linker Domain of Paramyxovirus HN Glycoprotein Is Essential for Triggering Virus Fusion.Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donorsImmunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignNew Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.Therapeutic efficacy of a respiratory syncytial virus fusion inhibitorUnderstanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.Influence of protein fold stability on immunogenicity and its implications for vaccine design.Ongoing developments in RSV prophylaxis: a clinician's analysis.A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.Structural basis for antibody-mediated neutralization of Lassa virus.Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Protection of calves by a prefusion-stabilized bovine RSV F vaccine.Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV.The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.
P2860
Q27333522-43CA22DE-E5D3-4B50-B409-2F326632FFB4Q28551865-50F2B0FC-C22B-480D-A455-35EDFA58B914Q30240274-33FD7F0F-0699-4813-A48D-524C1B10093FQ33775790-36F20D3C-C6FD-405D-B52D-960043E61356Q34547769-FC77030C-A40B-4DEC-B158-1EF526C34427Q35995788-0F3A00BB-A321-42C0-8026-35052A23F058Q36169170-9466F481-81B3-4C20-89F1-7C39D7EF579FQ36263882-1A3B30F0-D2CC-48DE-AC8D-B318497EBEF4Q36517337-F244E5C8-6B89-49A9-84ED-3F1E52AC5D02Q36973952-F301549E-7A7A-4853-9254-654B2D5AE161Q37002523-37AF5422-47E1-4E0E-8A9E-9CC7D36FF748Q37018347-C9FB1AF2-3DDB-4570-884E-8590DAB6A127Q37060986-A244D0BE-5EAD-4F7D-817D-E57237B9B72AQ37069783-74DDA7F0-0880-4B39-8C6A-72AFE13C8B69Q37086697-93136777-F29B-4E41-8079-491542378DEAQ37242530-63E5BBE7-2D0B-44F0-9609-A402244E3F7EQ37293748-B360CA1A-1CC6-4CDC-9672-612A09CE3A2CQ37300456-9FBF80F0-4D98-489F-A6B8-E26C261AC28BQ37347267-EAA0DCB6-E4A4-4FF4-9908-4647F05114FBQ37398188-284A7635-4C26-435D-89E3-2BCB4D0828E6Q37536191-5329A966-612B-43F5-AA13-D3056AD97D1DQ37593886-E8963B57-8E97-4ACE-B6F1-A865E6F999ABQ37729137-CD479206-F776-4417-BE71-3126D1E6E8F2Q38628928-BAF0EC0F-05FE-46C2-BE2F-3760F6BAB154Q38637248-9099A075-6D0B-4313-8368-45B91C15DE35Q38650711-FD88D2DC-E555-4863-A845-9C667B8AD12EQ38660842-77D0312F-32F2-4A48-A89A-613F3507E757Q38921013-757DADBA-1C98-40D8-95E3-4B83EBED7657Q39177220-CC70662A-70BD-4B04-A5E7-FEF096B8249EQ39303791-35D0B1DC-4BD3-415F-AF75-72882B3F85D4Q39362187-C7AB31DB-8778-451C-8780-A1F15101666CQ40054615-B66B0C67-6019-4547-A6FF-271EEEEADAFEQ40083207-9ECB473F-4A6E-4DE3-BDC8-13F77736225FQ40187606-38AE9E4F-A787-4FD7-B692-241B10D74D7BQ40244825-BFC4759A-44E6-4889-8A4D-C1CF33BAE542Q40812866-6ACC6134-3CA0-46CA-8AEF-C60E4AE8E313Q41918616-7935C0D9-9D50-4895-902F-301E1744183CQ42652733-83857CF5-7341-481E-A13B-EAA89980BB92Q45323698-73310B92-BD4F-4E18-92A6-9AD2A101D47FQ45324052-8B6FF1A3-E847-40C6-9C92-AEAF41B292A3
P2860
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@ast
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@en
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@nl
type
label
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@ast
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@en
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@nl
prefLabel
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@ast
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@en
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@nl
P2093
P2860
P356
P1476
A highly stable prefusion RSV ...... alysis of the fusion mechanism
@en
P2093
Anders Krarup
Daphné Truan
Hanneke Schuitemaker
Ilona J M Bisschop
Johannes P M Langedijk
Lies Bogaert
Myra N Widjojoatmodjo
Pascale Bouchier
Polina Furmanova-Hollenstein
Roland Zahn
P2860
P2888
P356
10.1038/NCOMMS9143
P407
P577
2015-09-03T00:00:00Z
P5875
P6179
1036731886